$AGEN

AGENUS INC (AGEN): Results of Operations and Financial Condition

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001098972 0001098972 2026-08-06 2026-08-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06

Original reporting
Published Aug 6, 2026, 11:52 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AGEN
Neutral
low confidence
Mentioned
$AGEN
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AGENNeutralLow
01

Why it matters

The filing itself signals that updated operating and financial condition information is available, but the provided text does not include the actual results or any forward-looking statements.

02

Market read

This is a primary disclosure event for AGEN, but the excerpt lacks the specific financial metrics that would drive trading decisions.

03

What to watch

Traders should verify Exhibit 99.1 for revenue, cash runway, burn rate, and any updated clinical or regulatory milestones, which are not present in the scraped body.

Relevance 7/10Novelty 3/10Timing: filed pre-market/early session on 2026-08-06

Background

The article is an SEC Form 8-K filing by Agenus, with Item 2.02 indicating results for the quarter ended June 30, 2026 and a furnished press release as Exhibit 99.1.

Company-level read

Ticker impact

$AGENNeutralLow confidence
Context

Agenus filed an 8-K furnishing its quarter ended June 30, 2026 results press release under Item 2.02.

Expected impact

Near-term price reaction is possible on the full Exhibit 99.1 details, but cannot be inferred from the provided body.

Evidence & confidence

The filing confirms results were announced and furnished, yet the excerpt contains no numbers, outlook, or qualitative drivers from Exhibit 99.1.

Market effects

Limited from the provided text, since no biotech/sector datapoints or peer read-across are disclosed.

None indicated in the excerpt.

None indicated in the excerpt.

Counterpoint

Because the excerpt omits Exhibit 99.1 content, the market may already have priced the results; the incremental value here is mainly the confirmation of filing rather than new fundamentals.

Key entities

  • Agenus Inc.

    Nasdaq-listed biotech company filing an 8-K to furnish its quarter ended June 30, 2026 results press release.

  • SEC Form 8-K

    Current report used to disclose results of operations and financial condition via Item 2.02.

Related articles

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.

$AGENMedAI 8/10

Why Is Agenus Stock Falling on Tuesday? - Agenus (NASDAQ:AGEN)

Agenus Inc. (NASDAQ:AGEN) shares fell Tuesday after a record Monday surge of about 95% to 111% amid profit-taking. On Monday, the company reported Phase 1b data for botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer, with median OS 21.2 months. Agenus also announced an $85M private placement plus up to $255M in warrants to fund its Phase 3 ROBBIN trial and shift from BATTMAN. HC Wainwright raised its AGEN price target to $30.

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.